NCI Technology Opportunities Webinar: T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias
Register and join to learn about a new T-cell receptor (TCR) that targets CD22, being developed by the National Cancer Institute (NCI) as a cellular immunotherapy for the treatment of lymphomas and leukemias. CD22 TCR-T cells cleared leukemia at clinically relevant doses without causing systemic cytokine elevation. This webinar will discuss (i) novel CD22 specific …